Onyx Pharmaceuticals (Onyx) has reported updated safety data from the pivotal Phase 2b 003-A1 study, known as the 003 trial, demonstrating that Carfilzomib is well-tolerated in heavily pre-treated
Boehringer Ingelheim has reported results from the Recover study investigating Dabigatran Etexilate (150 mg BID), a direct thrombin inhibitor (DTI), compared to dose-adjusted Warfarin in patients with acute
Alexion PharmaceuticalsSoliris (eculizumab) developed by Alexion, a first-in-class terminal complement inhibitor, was found to reduce hemolysis and transfusion requirements, and improved measures of fatigue, when added to ongoing
Amgen has presented results from the studies on the safety and efficacy of Nplate (Romiplostim) in adult patients with myelodysplastic syndromes (MDS). The results of the studies were
Gloucester has presented preclinical data, which demonstrates that the combination of Istodax (Romidepsin) and Velcade (Bortezomib) resulted in synergistic anti-tumor activity in B-cell non-Hodgkin’s lymphoma cell lines. Istodax
The FDA has approved Lilly’s Zyprexa (olanzapine) in tablet form as an option for the treatment of schizophrenia and manic or mixed episodes associated with bipolar I disorder
Allos Therapeutics (Allos) has entered into a collaborative agreement with Idis, to manage the named patient program for Folotyn (pralatrexate injection) outside of the US. The FDA has
Watson Pharmaceuticals (Watson) has confirmed that its subsidiary, Watson Laboratories has filed an Abbreviated New Drug Application (ANDA) with the FDA seeking approval to market its 8mg Ramelteon
The FDA has approved once-daily AstraZeneca’s Seroquel XR (quetiapine fumarate) extended release tablets as adjunctive treatment to antidepressants in adults with major depressive disorder (MDD). In addition to
Gwalia Packaging Group has received a contract to supplychild resistant containers and closers for multi-vitamins, reported packagingnews. Earlier in March 2008, the company had announced an investment programme,
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.